ECP is an established "second-line" treatment for CLAD/BOS. Recently, ECP was used for the first time in an adolescent CF patient as a "second-line" treatment therapy in life-threatening primary graft dysfunction following lung transplantation who deteriorated despite extensive treatment including ECMO and ATG. Within 10 days after initiation of ECP twice weekly, allograft function and clinical status improved significantly and the patient was weaned from mechanical ventilation support. ECP has been continued every 2 weeks since. Two hundred days after lung transplantation, the patient has an acceptable allograft function (FEV1 67%) and no signs of allograft rejection. We advocate that use of ECP and its immunomodulatory effects should be evaluated in the early period following lung transplantation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/petr.13145 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Short and Long-Term Outcomes of Lung Transplantation from Brain Death vs. Circulatory Death Donors: A Meta-analysis of Comparative Studies.
J Heart Lung Transplant
January 2025
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN; Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN. Electronic address:
Objectives: To investigate through a meta-analysis of comparative studies the impact of donor type (brain death DBD vs circulatory death DCD) on the short- and long-term outcomes of lung transplantation(LTx).
Methods: Literature search (terms "lung transplantation" AND "donation after circulatory death") was performed up to July 2022 and studies comparing outcomes of LTx from DCD versus DBD were selected. Primary endpoints were early and long-term mortality.
Scoliosis Progression after Lung Transplantation: Scoliosis after lung transplantation.
Spine J
January 2025
Department of Thoracic Surgery, Kyoto University, Graduate School of Medicine.
Background Context: Scoliosis is a potential postoperative complication of various pediatric cardiothoracic conditions.
Purpose: To investigate the incidence of scoliosis in pediatric lung transplant patients and explore the factors associated with its development.
Study Design: Retrospective observational study PATIENT SAMPLE: 330 consecutive lung transplant recipients at a single institution between April 2002 and June 2022.
In the Twilight of Evidence: Is Bypass Surgery Still on the Table for Cardiac Allograft Vasculopathy?
J Clin Med
December 2024
Department of Cardiology, University Hospital Zurich, 8091 Zurich, Switzerland.
Cardiac allograft vasculopathy (CAV) is a major prognosis-limiting factor in patients undergoing orthotopic heart transplantation (HT). Due to the diffuse involvement of the coronary tree, CAV lesions are often not amenable to percutaneous coronary intervention (PCI), leaving coronary artery bypass grafting (CABG) and retransplantation as primary revascularization options. : The latest guidelines from the International Society for Heart and Lung Transplantation (ISHLT) recognize CABG as a viable option but with a downgraded strength of recommendation.
View Article and Find Full Text PDFRecent Advances and Future Directions in Extracorporeal Carbon Dioxide Removal.
J Clin Med
December 2024
Department of Adult Critical Care, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners, London SE1 9RT, UK.
Extracorporeal carbon dioxide removal (ECCOR) is an emerging technique designed to reduce carbon dioxide (CO) levels in venous blood while enabling lung-protective ventilation or alleviating the work of breathing. Unlike high-flow extracorporeal membrane oxygenation (ECMO), ECCOR operates at lower blood flows (0.4-1.
View Article and Find Full Text PDFEngineered Cellular Therapies for the Treatment of Thoracic Cancers.
Cancers (Basel)
December 2024
Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
Thoracic malignancies (lung cancers and malignant pleural mesothelioma) are prevalent worldwide and are associated with high morbidity and mortality. Effective treatments are needed for patients with advanced disease. Cell therapies are a promising approach to the treatment of advanced cancers that make use of immune effector cells that have the ability to mediate antitumor immune responses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!